Full Name: A Randomized, Open-Label, Phase III Study of Nivolumab versus Chemotherapy in Patients with Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Fluoropyrimidine- and Platinum-Based Chemotherapy”
Purpose: Evaluate nivolumab (PD-1 inhibitor) versus standard chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) after first-line treatment failure.
Study Design:
- Phase III, randomized, open-label, multicenter trial
- Population: Patients with advanced ESCC who progressed after fluoropyrimidine + platinum chemotherapy
- Intervention:
- Nivolumab 240 mg IV every 2 weeks or 480 mg IV every 4 weeks
- Comparator: Physician’s choice of chemotherapy (paclitaxel or docetaxel)
Key Outcomes:
- Overall Survival (OS):
- Nivolumab significantly improved OS compared to chemotherapy (median OS ~10.9 vs 8.4 months).
- Progression-Free Survival (PFS):
- No significant difference; PFS similar between arms.
- Objective Response Rate (ORR):
- Slightly higher with nivolumab, but main benefit was survival and durability of response.
- Safety / Toxicity:
- Nivolumab: immune-related adverse events (pneumonitis, hepatitis, endocrinopathies, colitis), generally less grade ≥3 toxicity than chemotherapy.
- Chemotherapy: myelosuppression, neuropathy, alopecia, fatigue.
Pharmacist Considerations:
- Immune checkpoint inhibitor management:
- Monitor for immune-mediated toxicities (liver, thyroid, GI, lung, skin).
- Educate patients about early symptom recognition.
- Drug interactions: minimal for nivolumab (mostly supportive meds).
- Dosing & administration: IV infusion; ensure proper scheduling and infusion protocols.
- Supportive care: corticosteroids for immune-mediated adverse events; G-CSF or antiemetics for chemotherapy arm.
Significance: ATTRACTION-3 established nivolumab as standard second-line therapy for advanced ESCC, offering improved survival and a favorable safety profile compared to taxane chemotherapy.